A Breakthrough in Liver Health: Resmetirom and the Battle Against MASH
The approval of Resmetirom (Rezdiffra) by the Medicines and Healthcare products Regulatory Agency (MHRA) marks a significant milestone in the treatment of metabolic dysfunction-associated steatohepatitis (MASH). But what does this really mean for patients, and why should we care? Let’s dive in.
The Silent Epidemic of MASH
MASH is a condition where fat accumulates in the liver, leading to inflammation, scarring, and eventually, liver dysfunction. It’s the advanced stage of nonalcoholic fatty liver disease (NAFLD), a condition often linked to obesity, diabetes, and metabolic syndrome. What makes this particularly fascinating is how MASH has quietly become a global health crisis, affecting millions yet remaining underrecognized.
Personally, I think the lack of awareness around MASH is staggering. Unlike other chronic diseases, it often
